Evidence Mounts for Darolutamide Plus ADT in Hormone-Sensitive Prostate Cancer
WASHINGTON — Darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) significantly improved outcomes compared with ADT alone in men with metastatic hormone-sensitive prostate cancer (mHSPC), the phase II ARASEC trial showed. In the study, which used an external control arm from the historic CHAARTED trial, median progression-free survival (PFS) was not estimable with the combination of…
